Epidemiological burden of female genital tract cancers in the United States, 1999–2024
Annals of Middle Eastern Medicine · 2026
DOI: 10.24911/amem.15-3236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Middle Eastern Medicine, 2026. Verfasst von Yazeed Albalawi und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Female genital tract cancers (FGTCs) remain a leading contributor to women’s cancer mortality in the United States. This study provides the first comprehensive, population level assessment of temporal, demographic, and geographic patterns in FGTC mortality from 1999 through 2024.
Methodology: We extracted death certificate data from the CDC WONDER database (ICD10 C51–C58) and calculated crude and age adjusted mortality rates (AAMRs) per 100,000 women using the 2000 U.S. standard population. Trends were examined with Joinpoint regression to estimate annual percent change (APC). Analyses were stratified by age, race/ethnicity, census region, state, and NCHS urban–rural classification
Results: From 1999–2024, 850,404 deaths attributed to FGTCs were recorded. The overall AAMR was 10.6 per 100,000. Mortality declined from 1999 to 2018 (APC: –1.35, p = 0.0396), but a marked increase occurred between 2018 and 2021 (AAMR rising from 8.8 to 16.8 per 100,000), followed by stabilization through 2024. Pronounced disparities were observed: non Hispanic Black women experienced the highest average AAMR (21.6), followed by non Hispanic White (17.1) and American Indian/Alaska Native women (14.0). Regional and urban rural heterogeneity was evident with the Northeast and Midwest showing higher AAMRs and nonmetropolitan areas demonstrating persistently elevated rates; state level burdens peaked in the District of Columbia and several Appalachian states. The COVID19 pandemic coincided with the 2018–2021 mortality surge, likely reflecting diagnostic and treatment disruptions in addition to direct pandemic mortality.
Conclusion
Although FGTC mortality fell through 2018—coinciding with advances in screening, surgical deescalation, and targeted therapies—progress stalled and partially reversed around the pandemic period. Persistent racial, geographic, and rural–urban inequities underscore the need for equity focused interventions: reinforce screening and vaccination programs, expand access to specialty oncology care (including teleoncology and regional referral pathways), and prioritize policies that mitigate social determinants driving excess mortality.
Zitieren
APA
Albalawi, Y., Khormi, K., Almazroy, E. A., Alodayli, A., Alkhamisi, H., Alzahrani, L., Alkahtani, N., Alqahtani, M., Alaqil, A., Alsubait, B., & Althunayan, N. S. (2026). Epidemiological burden of female genital tract cancers in the United States, 1999–2024. Annals of Middle Eastern Medicine. https://doi.org/10.24911/amem.15-3236
Vancouver
Albalawi Y, Khormi K, Almazroy EA, Alodayli A, Alkhamisi H, Alzahrani L, et al. Epidemiological burden of female genital tract cancers in the United States, 1999–2024. Annals of Middle Eastern Medicine. 2026. doi:10.24911/amem.15-3236
BibTeX
@article{Albalawi2026,
author = {Albalawi, Yazeed and Khormi, Khaled and Almazroy, Eynar Abdulmoaatni and Alodayli, Ali and Alkhamisi, Haneen and Alzahrani, Lauy and Alkahtani, Norah and Alqahtani, Manar and Alaqil, Amjad and Alsubait, Batool and Althunayan, Nadiyah Salem},
title = {Epidemiological burden of female genital tract cancers in the United States, 1999–2024},
journal = {Annals of Middle Eastern Medicine},
year = {2026},
doi = {10.24911/amem.15-3236}
}
EUVIMED